[Severe familial hypercholesterolemia treatment]

Area of Science:

• Metabolic Disorders
• Cardiovascular Medicine
• Genetics

Background:

• Familial hypercholesterolemia (FH) is the most common inherited metabolic disorder, characterized by significantly elevated LDL-cholesterol levels.
• FH leads to a high risk of atherosclerotic cardiovascular disease, with clinical presentation varying based on genotype and risk factors.
• Identifying severely affected FH individuals is crucial for effective clinical management.

Purpose of the Study:

• To outline the complex and comprehensive therapeutic strategies for managing Familial hypercholesterolemia.
• To discuss the cornerstone pharmacotherapies and advanced treatment options for FH patients.
• To highlight the necessity of personalized treatment approaches for severe FH.

Main Methods:

• Review of current pharmacotherapy, including high-intensity statin therapy combined with ezetimibe and bile acid sequestrants.
• Exploration of advanced pharmacological interventions such as PCSK9 inhibitors, apoB-100 anti-sense therapy, and MTP inhibition.
• Discussion of non-pharmacological approaches including LDL-apheresis and liver transplantation for refractory cases.

Main Results:

• Standard multi-drug pharmacotherapy (statins, ezetimibe) often fails to achieve treatment goals for many FH patients.
• Advanced therapies are necessary when initial treatments are insufficient.
• Combinations of pharmacological and non-pharmacological methods are essential for managing severe FH.

Conclusions:

• Effective management of FH requires a multifaceted therapeutic approach.
• Advanced treatments like PCSK9 inhibitors, mipomersen, lomitapide, LDL-apheresis, and liver transplantation are vital for severe FH.
• Personalized and comprehensive treatment plans are key to reducing cardiovascular risk in FH patients.